AKARI THERAPEUTICS, PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.6 USD | -2.14% |
|
+17.65% | -48.72% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2022 | - | Sales 2023 | - | Capitalization | 17.64M |
|---|---|---|---|---|---|
| Net income 2022 | -17M | Net income 2023 | -10M | EV / Sales 2022 | - |
| Net cash position 2022 | 13.25M | Net cash position 2023 | 3.84M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.65
x | P/E ratio 2023 |
-1.53
x | Employees | 11 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 28.78% |
More Fundamentals
* Assessed data
More news
Latest transcript on Akari Therapeutics, Plc
More recommendations
More press releases
| 1 day | -2.14% | ||
| 1 week | +17.65% | ||
| Current month | +3.90% | ||
| 1 month | +23.08% | ||
| 3 months | -33.33% | ||
| 6 months | -52.66% | ||
| Current year | -48.72% |
1 week
1.17
1.75
1 month
1.081.87
Current year
1.083.30
1 year
1.085.50
3 years
1.0839.80
5 years
1.0884.20
10 years
1.08522.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 15-08-31 | |
Wendy DiCicco
DFI | Director of Finance/CFO | 56 | 23-07-18 |
Miles Nunn
CTO | Chief Tech/Sci/R&D Officer | - | 15-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donald Williams
BRD | Director/Board Member | 65 | 16-05-31 |
| Founder | 79 | 15-08-31 | |
| Director/Board Member | 61 | 23-07-04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 1.6 | -2.14% | 19,063 |
| 24-05-09 | 1.635 | +12.76% | 30,367 |
| 24-05-08 | 1.45 | 0.00% | 11,683 |
| 24-05-07 | 1.45 | +8.21% | 12,419 |
| 24-05-06 | 1.34 | -1.47% | 16,327 |
Delayed Quote Nasdaq, May 10, 2024 at 04:30 pm EDT
More quotes
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
Calendar
2024-05-29
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -48.72% | 12.96M | |
| +3.91% | 108B | |
| +10.87% | 104B | |
| +1.28% | 22.33B | |
| -13.14% | 22.19B | |
| -7.05% | 18.69B | |
| -38.36% | 17.74B | |
| -10.66% | 17.64B | |
| +3.75% | 14.05B | |
| +36.70% | 12.51B |
- Stock Market
- Equities
- AKTX Stock
